EUR 126.90 at Lang & Schwarz: Merck & Co. stock pre-market minus 0.60 percent versus the prior close
Published on 10/08/2026 at 07:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock was at EUR 126.90 pre-market at Lang & Schwarz at 7:46 a.m. CEST on October 8, 2026. The price was down 0.60 percent versus the prior close of EUR 127.66 on October 7, 2026.
Pre-market trading
Lang & Schwarz showed a bid of EUR 126.48 and an ask of EUR 127.32. The Xetra session remained ahead at the time of the quote. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Merck & Co. stock.
WINREVAIR label update
On September 22, 2026, Merck said the U.S. Food and Drug Administration had approved an update to the WINREVAIR label based on the Phase 3 HYPERION trial, according to Business Wire. The release said HYPERION enrolled 320 adults with newly diagnosed pulmonary arterial hypertension. Adding WINREVAIR to background therapy reduced the risk of clinical worsening events by 76 percent versus placebo, with a hazard ratio of 0.24. A first clinical worsening event occurred in 10.6 percent of patients receiving WINREVAIR and 36.9 percent of those receiving placebo. The release also described updated European Respiratory Society guidelines for pulmonary arterial hypertension treatment.
